Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
06 Juli 2009 - 2:11PM
PR Newswire (US)
NEW YORK, July 6 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a medical technology company testing its
proprietary treatment method for primary and metastatic cancers to
the liver, announced today that Eamonn P. Hobbs, 51, a member of
the Delcath Board of Directors since October 2008, has been
appointed President and CEO of the Company. Mr. Hobbs succeeds
Richard Taney who has led the company since December 2006 and will
continue to serve on the Company's Board of Directors. (Logo:
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Mr.
Hobbs has over 25 years of experience in the interventional
radiology, interventional cardiology and gastroenterology medical
device industries. From 1988 until earlier this year, Mr. Hobbs was
President and CEO of AngioDynamics, Inc. (NASDAQ:ANGO). As a
co-founder, he built AngioDynamics into a leading medical
technology company with an international market presence and a
highly diverse product line. Throughout his tenure at
AngioDynamics, Mr. Hobbs led the Company's efforts in marketing,
strategic planning, product development, and general management. In
2004, AngioDynamics was spun off from E-Z-EM, Inc., a healthcare
company focused on diagnostic technologies, where Mr. Hobbs served
as Senior Vice-President since 1988. Before his involvement with
these companies, Mr. Hobbs was the Director of Marketing and
Product Development at NAMIC, Founder, President and CEO of Hobbs
Medical, Inc., and a Product Development Engineer at Cook
Incorporated. He received a Bachelor of Science in Plastics
Engineering with a Biomaterials emphasis at the University of
Massachusetts in 1980. In addition, Mr. Hobbs was elected to and
currently serves on the Board of Directors of the Society of
Interventional Radiology Foundation and as Vice Chairman of the
Medical Device Manufacturers Association. Commenting on his new
position at Delcath, Mr. Hobbs stated, "I am delighted to be
leading Delcath during this exciting time in our development.
Richard has done an exceptional job leading the Company over the
past two-plus years and I look forward to building on recent
achievements. The promise of our drug delivery platform and its
unique position in the interventional oncology space offers the
opportunity to address a large and growing unmet medical need. I
look forward to completing our Phase III clinical trials and
submitting for FDA approval in a timely manner. At the same time,
we will focus on expanding our presence and relationships within
the medical community and look forward to delivering this exciting
treatment modality to oncology patients worldwide." "Eamonn is a
proven leader with extensive experience in all aspects of medical
device commercialization and the entire Board feels that he is the
best person to lead our Company through the next phase of our
development," added Dr. Harold Koplewicz, Chairman of Delcath's
Board of Directors. Commenting on this transition, Mr. Taney
stated, "The Delcath management team and our Board of Directors are
very proud of the tremendous progress our Company has made over the
past two and a half years. As we approach completion of our pivotal
Phase III trial, we are increasingly shifting our focus towards the
commercialization of our technology. I look forward to working with
Eamonn during this transition and to my continued involvement as a
committed member of our Board of Directors." About Delcath Systems,
Inc. Delcath Systems, Inc. is a medical device company specializing
in cancer treatment. The Company is testing a proprietary, patented
drug delivery system for the treatment of liver cancers. Delcath's
novel drug delivery platform is testing the delivery of ultra-high
doses of anti-cancer drugs to the liver while preventing these high
doses of drug from entering the patient's bloodstream. The Company
is currently enrolling patients in Phase III and Phase II clinical
studies for the treatment of liver cancers using high doses of
melphalan. The Company's intellectual property portfolio consists
of twenty-seven patents on a worldwide basis including the U.S.,
Europe, Asia and Canada. For more information, please visit the
Company's website at http://www.delcath.com/. The Private
Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf.
This news release contains forward-looking statements, which are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to,
uncertainties relating to our ability to successfully complete
Phase III clinical trials and secure regulatory approval of our
current or future drug-delivery system and uncertainties regarding
our ability to obtain financial and other resources for any
research, development and commercialization activities. These
factors, and others, are discussed from time to time in our filings
with the Securities and Exchange Commission. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date they are made. We undertake no obligation to
publicly update or revise these forward-looking statements to
reflect events or circumstances after the date they are made.
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO
http://photoarchive.ap.org/ DATASOURCE: Delcath Systems, Inc.
CONTACT: Investor, Steve DiMattia, Managing Director of EVC Group,
Inc., +1-646-201-5445, , or Media, Robin Wagge, Senior Vice
President of Rubenstein Associates, for Delcath Systems, Inc.,
+1-212-843-8006, Web Site: http://www.delcath.com/
Copyright